METOPROLOL TARTRATE INJECTION USP SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

METOPROLOL TARTRATE

Pieejams no:

SANDOZ CANADA INCORPORATED

ATĶ kods:

C07AB02

SNN (starptautisko nepatentēto nosaukumu):

METOPROLOL

Deva:

1MG

Zāļu forma:

SOLUTION

Kompozīcija:

METOPROLOL TARTRATE 1MG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

5ML

Receptes veids:

Prescription

Ārstniecības joma:

BETA-ADRENERGIC BLOCKING AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0111923004; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2005-09-02

Produkta apraksts

_Metoprolol Tartrate Injection USP _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
INCLUDING CONSUMER INFORMATION
PR
METOPROLOL TARTRATE INJECTION USP
(metoprolol tartrate)
5 mL vials (1 mg/mL)
β-Adrenergic Receptor Blocking Agent
Sandoz Canada Inc.
Date of Revision: August 10, 2020
110 Rue de Lauzon
Boucherville, QC, Canada
J4B 1E6
Submission Control No: 240543
_Metoprolol Tartrate Injection USP _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
10
DOSAGE AND ADMINISTRATION
.....................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
21
STORAGE AND STABILITY
.................................................................................................
25
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
25
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................... 25
PART II: SCIENTIFIC INFORMATION
...............................................................................
26
PHARMACEUTICAL INFORMATION
.................................................................................
26
DETAILED PHARMACOLOGY
............................................................................................
27
TOXICOLOGY...........